Cancer Biopsy Market Overview

The Cancer Biopsy Market is projected to witness significant growth from 2025 to 2033, driven by the increasing incidence of cancer. Valued at approximately USD 32.9 billion in 2025, the market is expected to surge to USD 62.7 billion by 2033, reflecting a strong compound annual growth rate (CAGR) of 8.4% over the ten-year period.

A cancer biopsy is a vital diagnostic procedure where tissue or cell samples are taken from a suspected tumor and analyzed under a microscope to confirm the presence of cancer. It helps determine the cancer type, stage, and aggressiveness, guiding treatment decisions and predicting outcomes. Various biopsy methods are used depending on the clinical need—needle biopsies like fine-needle aspiration (FNA) and core needle biopsy (CNB), surgical options such as excisional and incisional biopsies, and endoscopic or liquid biopsies that involve minimal invasion. Beyond diagnosis, biopsies are essential for cancer staging, helping doctors assess how advanced the disease is and choose appropriate treatments like chemotherapy, immunotherapy, or targeted therapies. They also help monitor treatment effectiveness. The development of liquid biopsies has enabled early cancer detection and non-invasive screening. Additionally, genetic profiling from biopsies supports personalized medicine by tailoring therapies to individual mutations. Overall, biopsies play a critical role in comprehensive cancer care.

Furthermore, genetic profiling from biopsies has made personalized medicine possible, whereby treatments are tailored to the patient based on their own genetic mutations. Through proper diagnosis, staging, and monitoring of therapies, biopsies remain the cornerstone of oncology, significantly contributing to improved patient care and outcomes.

Cancer Biopsy Market Drivers and Opportunities

Rising Incidence of Colorectal Cancer and Gastrointestinal Disorders to Propel Cancer Biopsy Market Growth

The increasing global burden of cancer, particularly colorectal cancer and gastrointestinal disorders, is expected to drive significant growth in the cancer biopsy market over the forecast period. According to the World Health Organization (WHO), cancer remains a leading cause of death worldwide, with an estimated 20 million new cases and 9.7 million deaths reported in 2022. Approximately 1 in 5 individuals will develop cancer in their lifetime, highlighting the urgent need for accurate and early diagnostic solutions. This surge in cancer cases is fueling demand for both conventional biopsy techniques—such as needle and surgical biopsies—and the growing adoption of non-invasive liquid biopsies.

Technological Advancements Fueling Market Expansion

Innovations in biopsy technologies are further accelerating market growth. The integration of liquid biopsy, AI-driven pathology, and next-generation sequencing (NGS) is enhancing diagnostic precision and efficiency. Liquid biopsies, which detect circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) through simple blood draws, offer real-time monitoring with minimal patient discomfort. Meanwhile, AI is streamlining pathology workflows and reducing diagnostic errors, positioning these advancements as key enablers in modern oncology.

Opportunity for the Cancer Biopsy Market

Rising Embrace of Personalized Medicine Presents Key Opportunities in the Global Cancer Biopsy Market

The growing shift toward personalized medicine represents a significant opportunity for expansion in the cancer biopsy market. As oncology treatments become more targeted and individualized, the need for biopsies that offer detailed genetic and molecular insights into tumors is increasing. Biomarker-driven diagnostics are central to personalized medicine, enabling tailored therapies that enhance treatment effectiveness while minimizing adverse effects.

Liquid biopsy, in particular, is transforming precision oncology by enabling real-time tumor monitoring through non-invasive methods, eliminating the need for repeated surgical procedures. This approach not only improves patient comfort but also enhances clinical decision-making. With pharmaceutical companies and healthcare providers placing greater emphasis on customized treatment strategies, the demand for advanced biopsy technologies is expected to surge, creating substantial opportunities for innovation and growth in the global market.

Cancer Biopsy Market Scope

Cancer Biopsy Market Report Segmentation Analysis

The global Cancer Biopsy Market industry analysis is segmented into by Product, by type of Biopsy, by Application, by End-user and by region.

The Kits and Consumables segment is anticipated to hold the major share of the global Cancer Biopsy Market during the projected timeframe.Kits and Consumables are set to dominate the largest share of the global cancer biopsy market as demand for the procedure increases and disposable products are frequently used. Consumables, including biopsy needles, reagents, and collection tubes, are essential to sample collection, storage, and analysis, and hence create stable demand from all health facilities.

Rise in the use of liquid biopsy, wherein specialized consumables are utilized to detect circulating tumor DNA (ctDNA) and extracellular vesicles, is also propelling growth in the market. In addition, advancements in molecular diagnostics and personalized medicine are generating demand for high-quality biopsy kits that enable accurate detection of cancer biomarkers.

The Needle Biopsy segment is anticipated to hold the highest share of the global Cancer Biopsy Market during the projected timeframe.Needle Biopsy segment is poised to hold the largest market share as it is minimally intrusive and highly accurate. Fine needle aspiration biopsy (FNAB) and core needle biopsy (CNB) are frequently used to diagnose cancers of the breast, lung, and prostate. Rising incidence of these cancers and popularity of outpatient treatments that avoid hospitalization are fuelling demand for needle biopsy. In addition, use of imaging modalities such as ultrasound and MRI-guided needle biopsies is increasing accuracy and fuelling growth.

The Breast Cancer application segment is anticipated to hold the highest share of the market over the forecast period.Breast Cancer application segment would hold the largest share as the occurrence of breast cancer is increasing around the world. Detection at an early stage by means of biopsy processes is crucial to maximize survival. Liquid biopsy and needle biopsy are commonly used to diagnose and monitor breast cancer, allowing for better decision-making during treatments. Growth is also spurred by the increasing use of genetic testing and analysis of biomarkers.

The Hospital & Clincis end-user segment dominated the market in 2024 and is predicted to grow at the highest CAGR over the forecast period.

Hospitals & Clinics segment had the highest share of the market in 2024 and is expected to grow at the highest Compound Annual Growth Rate (CAGR) as sophisticated biopsy technologies and skilled health professionals are easily accessible. Hospital and specialized cancer clinics perform most of the biopsies as they are equipped with advanced diagnostic machinery and labs. The growth of the segment is also driven by the growing number of cancer treatment centers and government initiatives to promote early detection of cancer.

The following segments are part of an in-depth analysis of the global Cancer Biopsy Market:

Cancer Biopsy Market Share Analysis by Region

North America is projected to hold the largest share of the global Cancer Biopsy Market over the forecast period.

North America is anticipated to hold the largest share of the global cancer biopsy market throughout the forecast period, driven by a high cancer prevalence, advanced healthcare infrastructure, and widespread adoption of cutting-edge diagnostic technologies. According to the American Cancer Society, approximately 2 million new cancer cases are expected to be diagnosed in the U.S. alone in 2024, with lung, breast, prostate, and colorectal cancers being the most common. This rising cancer burden is accelerating the need for accurate and early diagnostic methods, such as liquid biopsies, fine needle aspiration, and core needle biopsies.

Liquid biopsy, in particular, is rapidly gaining popularity due to its non-invasive nature and ability to detect cancer at early stages. Furthermore, the region benefits from robust government support and funding for cancer research, the presence of major industry players, and a well-established reimbursement system. Growing emphasis on personalized medicine and targeted therapies is further boosting demand for advanced biopsy techniques to identify genetic mutations and tumor-specific markers.

Cancer Biopsy Market Competition Landscape Analysis

The market is competitive, with several established players and new entrants offering a range of cancer biopsy products. Some of the key players QIAGEN, Epigenomics AG, BD (Becton, Dickinson and Company), Biocept, Inc., F. Hoffmann-La Roche Ltd., Danaher and others.

Global Cancer Biopsy Market Recent Developments News:

• In April 2023, Quest Diagnostics announced a definitive agreement to acquire Haystack Oncology, an early-stage oncology company specializing in minimal residual disease (MRD) testing for early and accurate detection of residual or recurrent cancer. The acquisition, structured as an all-cash equity transaction, aims to enhance Quest’s capabilities in precision cancer diagnostics and informed treatment decision-making.
• In March 2021, Agilent Technologies Inc. revealed it had entered into a definitive agreement to acquire Resolution Bioscience Inc., a leading provider of next-generation sequencing (NGS)-based precision oncology solutions. This strategic acquisition strengthens Agilent’s portfolio in NGS cancer diagnostics and adds cutting-edge technologies to better meet the demands of the growing precision medicine market.
• In May 2024, Inocras and IMBdx announced a strategic collaboration to improve cancer patient care in the U.S. The partnership combines Inocras’s expertise in whole genome sequencing diagnostics with IMBdx’s leadership in liquid biopsy-based cancer detection, offering comprehensive solutions to patients and healthcare providers.

The Global Cancer Biopsy Market is dominated by a few large companies, such as

●       QIAGEN

●       Epigenomics AG

●       BD (Becton, Dickinson and Company)

●       Biocept, Inc.

●       Danaher

●       Exact Sciences Corporation

●       F. Hoffmann-La Roche Ltd.

●       Freenome Holdings, Inc.

●       GRAIL, Inc.

●       Guardant Health Inc.

●       Hologic, Inc.

●       Illumina, Inc.

●       Lucence Health Inc.

●       Myriad Genetics, Inc.

●       Thermo Fisher Scientific, Inc.

●       Other Prominent Players